Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions

The ROS1 tyrosine kinase inhibitor (TKI) crizotinib has shown dramatic effects in patients with non‐small cell lung cancer (NSCLC) harboring ROS1 fusion genes. However, patients inevitably develop resistance to this agent. Therefore, a new treatment strategy is required for lung tumors with ROS1 fus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Kato, Yuka, Ninomiya, Kiichiro, Ohashi, Kadoaki, Tomida, Shuta, Makimoto, Go, Watanabe, Hiromi, Kudo, Kenichiro, Matsumoto, Shingo, Umemura, Shigeki, Goto, Koichi, Ichihara, Eiki, Ninomiya, Takashi, Kubo, Toshio, Sato, Akiko, Hotta, Katsuyuki, Tabata, Masahiro, Toyooka, Shinichi, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6172052/
https://ncbi.nlm.nih.gov/pubmed/30053332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13752
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados